FindTrial
Sign In

A study to assess the combination of Famotidine and Celecoxib in patients COVID-19

A Pilot Randomized Study to Evaluate the Safety and Efficacy of Drug Combination of Famotidine and Celecoxib in COVID-19 Patients. - FAMCOX trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045626
Enrollment
62
Registered
2022-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Famotidine and Celecoxib with standard care: Famotidine - 80 mg 4 times a day for 14 days Celecoxib - one time first dose of 400 mg and then 200 mg twice a day for 5 days Control Interv

Sponsors

Sir Hurkisondas Nurrotumdas Reliance Foundation Hospital and Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients that are 18 years old and above who tested positive for COVID-19 using RT-PCR test 2. WHO Clinical Progression Ordinal Scale scores between 1ââ?¬â??5 3. Informed consent signature.

Exclusion criteria

Exclusion criteria: 1. WHO Clinical Progression Ordinal Scale scores of >5 2. Subjects with documented cardiac problem. 3. Subjects with diabetic nephropathy or chronic kidney disease ââ?¬â?? stage 3. eGFR 4. Known case of cancer. 5. Pregnant or nursing women. 6. Known allergy of COX2 inhibitor. 7. Subjects on Dexamethasone. 8. Belonging to another clinical trial that evaluates the efficacy of an investigational drug against COVID-19. The use of other treatments outside of clinical trials is allowed.

Design outcomes

Primary

MeasureTime frame
Changes in C-reactive protein levels measured using blood test. Progression and resolution of complication and symptoms will be measured using the WHO Clinical Progression Scale. Viral load will be measured using Ct value from RT-PCR test. Timepoint: C-reactive protein - day 0,2,5,10,30 WHO Clinical Progression Scale- Day 0,1,2,3,5,10,30,60,90 RT-PCR test - Day 0, 3,5,10,30—

Secondary

MeasureTime frame
Resolutions of anosmia, cough, fever and other patient complaints. Changes in other inflammatory markers (Blood tests for Interleukin-6 (IL6), D-Dimer (DD), Lactate dehydrogenase enzyme (LDH) and Serum ferritin (SF)) Timepoint: Resolution of complaints - day 0,2,3,5,10,30,60,90 Other inflammatory markers - day 0,2,5,10,30—

Countries

India

Contacts

Public ContactDr Muffazal Lakdawala

Sir Hurkisondas Nurrotumdas Reliance Foundation Hospital and Research Centre

Muffazal.Lakdawala@rfhospital.org9769162040

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026